Please login to the form below

Not currently logged in

People, January, 2011

Recent high-profile moves in the pharmaceutical and healthcare industriesMover of the month is Ian Read who has been appointed chief executive officer of Pfizer

Mover of the month

 Ian Read, CE Pfizer

Following the sudden departure of Jeff Kindler, Ian Read has been appointed chief executive of Pfizer. After receiving his BSc in chemical engineering from Imperial College London, Ian began his career with Pfizer in 1978 as an operational auditor. He worked in Latin America until 1995 and in 1996 he was appointed president of Pfizer's International Pharmaceuticals Group, with responsibility for Latin America and Canada. He became executive vice president, Europe in 2000, was named a corporate vice president in 2001, and assumed responsibility for Canada, in addition to Europe, in 2002, later also becoming responsible for Africa/Middle East and Latin America, and being appointed senior vice president. From 2006 to December 2010, Ian served as group president of the Worldwide Biopharmaceutical Businesses.

Kenneth C Frazier, Merck's president since May and an 18-year veteran of the firm, has been named by the company's board of directors to take on the additional role of chief executive officer, effective January 1. Frazier succeeds Richard T Clark, who became president and CEO in 2005. Frazier took on the role of company president in 2010, focusing largely on the integration of Merck and Schering-Plough after the $49bn merger of the two companies that took place in 2009 under Clark's leadership. Before being named president of the company, Frazier spent three years as president of Merck's global human health division. He began his career with the company in 1992 as vice president, general counsel and secretary of the Astra Merck Group. He made a name for himself as Merck's general counsel during the company's legal troubles after the painkiller Vioxx was withdrawn from the market.

Kenneth Frazier, CEO Merck

Veronique Walsh, BUD, BMS  

Bristol-Myers Squibb UK has appointed Dr Véronique Walsh as business unit director, neuroscience and immunoscience. Véronique, who will report into Amadou Diarra, vice president and general manager, BMS UK, has 20 years' experience in the vaccines industry. Before joining BMS, she worked at Sanofi Pasteur MSD UK where she was deputy managing director in charge of market access, public affairs, communications and strategic planning roles.

Stefan Oschmann has moved from Merck US, where he ran the emerging markets division, to Merck KGaA where, following the departure of Elmar Schnee, he will run the pharmaceuticals division.

 Stefan Oschmann, Merck KGaA

Guy Pedelini VP, Idis

Idis, a consultancy that partners with pharmaceutical and biotechnology companies across the life cycle of drug development, has appointed Guy Pedelini to the position of vice president of global human resources.

Refreshed Wellbeing, the digitally focused healthcare communications agency formed in September 2009, has recently appointed George Teague as its creative director. George's previous agencies include Lintas and DDB Health, where he developed campaigns for Schering-Plough, Roche, Bayer and Novo Nordisk. George has also run his own creative business, Gorgeous Creative, where he was involved in the start-up and branding of online businesses such as

George Teague, CD, Ref Wellbeing



Ellen Sarewitz, DCS, MedicusClaudia Pena Murillo, Medicus

Ellen Sarewitz joins Medicus International as director of client services. Ellen, who has over 20 years' healthcare experience, was previously head of international healthcare at Munro & Forster. Dr Claudia Peña Murillo joins the agency as associate medical writer, providing additional support to the Boehringer Ingelheim oncology accounts.

David Fisher has been appointed managing director of PMGroup, replacing the company's founder Mark Savage who has assumed the role of CEO. David, former commercial director with The Association of the British Pharmaceutical Industry (ABPI), has more than 25 years' experience within the international pharmaceutical industry working with Ciba Geigy, Pfizer and sanofi-aventis. David will join Mark, company secretary Trish Savage and non executive director Dawn Stallwood, founder and owner of consultancy Dantree, on the board of the independent publishing company.

David Fisher, MD PMGroup
David Rowley & Sandy Royden

Chime Communications has announced the launch of a new joint venture in the healthcare communications arena led by David Rowley, former global head of Huntsworth Health, and Sandy Royden, formerly head of Europe at Huntsworth Health. The new company will be the first discipline- and channel-neutral group in the healthcare arena and will be built through organic growth and focused acquisitions. "Combining our experience in the health space with the resources of Chime, will, we believe, result in a brand new type of health communications practice that will help our clients adapt successfully to a rapidly evolving marketplace," said Rowley. Lord Bell, chairman of Chime Communications said: "Health is one of the fastest growing sectors in communications, and we have been very impressed with both David and Sandy's track record, but more importantly, their insight into how together we can build a market-leading business."

e-Therapeutics has announced that Steve Self, development director, has agreed to join the company's board as an executive director. Steve has worked previously as group vice president, project management at Wellcome Research, head of respiratory and analgesic product development at Boots Healthcare International and European technical director (later group R&D director) at Merck Generics.

Hybrigenics, a biopharma firm focused on R&D of new cancer treatments with a fully-owned subsidiary specialising in protein interactions services, has hired William Vickery as head of corporate and business development, a newly created position. William worked for five years at ExonHit Therapeutics as senior director of business development. Prior to this, he was business development director of Roche Pharmaceuticals in the US and held various positions at Roche Pharmaceuticals headquarters in Switzerland, including business development responsibilities for CNS and metabolic diseases.

Global market research agency Synovate has appointed Chris King to the role of head of the European oncology monitor within its specialist healthcare research division. Most recently a senior consultant at Datamonitor, Chris has worked with Novartis Vaccines and also spent six years working at the British Columbia Cancer Research Centre.

Interlace Global Group has appointed new staff to its client services and editorial teams to work for twin companies Wells Healthcare and Interlace Global Communications. The Group has appointed three medical writers: registered pharmacist Isobel Strang, previously a senior scientist with AstraZeneca; Julianna Solomons, an academic with a background in HIV research, and Sandra Boswell, a medical biochemist with a PhD in immunology, allergy and asthma. Additionally, Raj Jangra joins the Group as account director. Raj has over 10 years' experience in tactical and strategic healthcare communications. The Group has also appointed four assistant account managers: Becky Butlin, who has a first class honours degree in physiology, specialising in neuroscience; Rajeeb Bilkhu, a pharmacologist who has worked closely with Pfizer; Emma Shapiro, who has an honours degree in medical science, and Jemma White, who joins from Novacta Biosystems where she was a senior research scientist.

Anna Garofalo has joined medeConnect, the market research arm of, as managing director. Anna joins the team from Double Helix where she was part of the senior leadership team, as director of strategic marketing research. She will  be responsible for all business operations, overseeing the research team and providing strategic marketing information and business insight to the healthcare and pharmaceutical sectors.

Interactive Medica has appointed Andrew Leeder as a key account manager. Previously Andrew held positions of commercial director at Conigi along with client development roles at Binleys, Dendrite, Synavant and IMS Health.

Central London Community Healthcare NHS Trust (CLCH) has announced the appointment of James Reilly as chief executive. James joins CLCH from his current role as director of community services for the London Borough of Hammersmith and Fulham. James will join CLCH early in 2011, taking over from current chief executive Claire Holloway, who will remain in post until that time.


Related links

FAQ: How do I get my move listed


Subscribe to our email news alerts


Add my company
dna Communications

Because health means everything...

Latest intelligence

New Playbook Alert: Virtual Patient Engagement
Millennials: the wellness generation
Looking at the results from a global healthcare research study focusing on the patients of the future...
The problem with clinical trials (and how virtual insight-gathering can help)
While still the gold standard of research, clinical trials are often riddled with issues that limit their applicability to broader populations or delay market access....